Home > Boards > US Listed > Biotechs > Cyclo Therapeutics (CYTH)

HOD $6.74 down to $5.60 stop-loss within 40 minutes.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Pedro2004 Member Profile
 
Followed By 98
Posts 8,831
Boards Moderated 0
Alias Born 08/03/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/15/2021 3:40:03 PM
Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit Business Wire - 9/15/2021 8:05:00 AM
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference Business Wire - 9/8/2021 8:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2021 5:08:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/31/2021 2:42:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:51:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:05:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:05:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:05:01 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:04:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:03:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/30/2021 7:03:12 PM
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Business Wire - 8/17/2021 8:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2021 4:52:43 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/16/2021 4:36:49 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2021 4:03:37 PM
Cyclo Therapeutics reports new positive data from early-stage rare genetic disorder study Seeking Alpha - 7/30/2021 8:37:03 AM
Cyclo Therapeutics Announces New Positive Safety and Efficacy Data from Ongoing Phase 1 Open-Label Extension Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 Business Wire - 7/30/2021 8:05:00 AM
Cyclo Therapeutics Commences Commercial-Scale Manufacturing for Trappsol® Cyclo™ Business Wire - 7/27/2021 8:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2021 4:04:09 PM
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation Business Wire - 6/21/2021 8:05:00 AM
Cyclo Therapeutics soars 10% on launch of Phase 3 Trappsol Cyclo study in rare genetic disorder Seeking Alpha - 6/17/2021 8:28:24 AM
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Ni... Business Wire - 6/17/2021 8:05:00 AM
Cyclo Therapeutics Announces Launch of New Website Business Wire - 6/15/2021 8:05:00 AM
Pedro2004   Tuesday, 01/05/21 11:12:53 AM
Re: Pedro2004 post# 18
Post # of 22 
HOD $6.74 down to $5.60 stop-loss within 40 minutes.

Definitely a pump and dump




It is, what it is.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences